据《The Hill》报道,在生物技术公司谴责FDA拒绝审评其mRNA流感疫苗后,FDA予以反击。2月10日,Moderna表示,其mRNA-1010疫苗的申请收到了FDA生物制品评估和研究中心(CBER)的拒绝受理函(RTF),并抨击美国方面提供的反馈“前后矛盾”。争议的核心在于Moderna在其III期临床试验中选择了一款已获批的季节性流感疫苗作为对照。而FDA早在2024年就曾表示,...
Source Link据《The Hill》报道,在生物技术公司谴责FDA拒绝审评其mRNA流感疫苗后,FDA予以反击。2月10日,Moderna表示,其mRNA-1010疫苗的申请收到了FDA生物制品评估和研究中心(CBER)的拒绝受理函(RTF),并抨击美国方面提供的反馈“前后矛盾”。争议的核心在于Moderna在其III期临床试验中选择了一款已获批的季节性流感疫苗作为对照。而FDA早在2024年就曾表示,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.